Program
Cholestyramine Resin
Also written as “Cholestyramine”, “cholestyramine” and “A3384”.
Its studies are mostly in Multiple Sclerosis · Hypercholesterolemia · Liver Cirrhosis, Biliary · Short Bowel Syndrome, led by 4 companies.
Drug pageCholestyramine Resin: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 61 open or running | phase 3since May 23, 2013 | May 23, 2013 | May 16, 2031phase 3 · NCT07930624 |
| Ipsenits history only | 20 open or running | phase 2since Mar 3, 2014 | Mar 3, 2014 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 1since Jun 6, 2023 | Jun 6, 2023 | none ahead |
| Pharmascience | 10 open or running | phase 2since Jul 26, 2019 | Jul 26, 2019 | none ahead |
Also a collaborator on its studies: Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmascience only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2019First study: phase 2 study in Short Bowel SyndromeFirst studyNCT04046328 · 13 enrolled · Poland
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Pharmascience leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04046328Short Bowel Syndrome · Poland | 2 | Terminated | Dec 22, 2021 | 13 |
How it is read
Names in the registry
- “Cholestyramine”, 4 entries
- “cholestyramine”, 3 entries
- “A3384”, 1 entry
- “CRC (A3384)”, 1 entry
- “Questran”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 3 studies
- Hypercholesterolemia, 3 studies
- Liver Cirrhosis, Biliary, 1 study
- Short Bowel Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.